Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002393 · ClinicalTrials.gov registry record · Phase 3
A Study of Indinavir Taken With or Without DMP 266
A Phase 3 study, sponsored by Dupont Merck.
- Completed
- Registry status
- Phase 3
- Development phase
- 300
- Enrollment target
NCT00002393: Completed Phase 3 study, sponsored by Dupont Merck.
NCT00002393 is a Phase 3 study that has completed, run by Dupont Merck. The registered enrollment target is 300 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (61% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002393, a Phase 3 study, has completed, sponsored by Dupont Merck.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 300 participants
- Enrollment target
Study Summary
The purpose of this study is to see if it is safe and effective to add DMP 266 to an anti-HIV treatment program of indinavir and nucleoside reverse transcriptase inhibitors (NRTIs).
Interventions
- DRUG Efavirenz
- DRUG Indinavir sulfate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Phase | Phase 3 |
What the finished NCT00002393 record still lists
NCT00002393 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (61% lower).
The record links to 0 conditions, and to 2 interventions - of which Efavirenz is the first listed.
NCT00002393 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002393 about?
NCT00002393 is a clinical study titled "A Study of Indinavir Taken With or Without DMP 266". The purpose of this study is to see if it is safe and effective to add DMP 266 to an anti-HIV treatment program of indinavir and nucleoside reverse transcriptase inhibitors (NRTIs).
What is the current status of trial NCT00002393?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 300 participants.
What interventions are being tested in trial NCT00002393?
The interventions under investigation include: Efavirenz (DRUG), Indinavir sulfate (DRUG).
Who is sponsoring clinical trial NCT00002393?
This trial is sponsored by Dupont Merck, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00002393's enrollment target sits among peer trials
300 1122nd of 2000 higher than 840 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics